All In Biotech

Drug Trial Radar · NCT02361216

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 729 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

729

Actual

Start

Apr 2015

Primary completion

Mar 2016

Study completion Mar 2017

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Feb 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol MebutateDrug

  • VehicleOther

    Vehicle gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laser & Skin Surgery Center of Indiana

    Carmel, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.